Trial Name Description
ARREST-2 MS Dr. Timothy Nguyen
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
IND.228 Dr. Eric Winquist
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours.
GARNET MS Dr. S. Welch
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
PM.1 MS Dr. S. Welch
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) A Phase II Basket Trial
STOP-NSCLC Dr. David Palma
Sterotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer
SABR-COMET-3
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 metastases) cancer. SABR-COMET-3
RT-NOW MS Dr. D. Palma
Is radiation-before-pathology a feasible approach in the palliative oncology setting? A pragmatic clinical trial
NAVIGATE MS Dr. S Ernst
A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRK Fusion-Positive Tumors. For melanoma and non-secretory breast cancer.
SABR-SYNC MS Dr. D. Palma
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients with Up to 10 Oligometastases and a Synchronous Primary Tumor
SUPR-3D Dr. Joanna Laba
SUPR-3D: A Randomized Phase III Trial Comparing Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients with Bone Metastases.
SEACRAFT-1 MS Dr. E. Winquist
Not open yet - An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations
Keynote 587 MS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
TAPISTRY MS Dr. S. Welch
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
CATCH-R GYN Dr. Stephen Welch
"Not Open Yet" CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy with Rucaparib
FMT-LUMINate NSCLC-MEL Dr. J. Raphael
Phase II Trial of Fecal Microbial Transplantation in Patients with Advanced Non-Small Cell Lung Cancer and Melanoma Treated with Immune Checkpoint Inhibitors (FMT-LUMINate)
INCB99280-204 Dr. Daniel Breadner
Not Yet Open - A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation